Collagen Solutions Share Discussion Threads

[tpau] 22/12/2014 14:36

Got a few more

[the prophet] 22/12/2014 11:25

brokers note indicated there were quite a few deals in the offing, good to see them coming through.
Pity about the long term chart in the header, I will ask advfn if they can sort it out.

[doodlebug4] 22/12/2014 10:46

Looks like private investors as well as fund managers are beginning to waken up to the potential here.

"The long term provision of our medical grade collagen for an increasing number of products begins to unlock the value that we have in our manufacturing capabilities."

[the prophet] 22/12/2014 10:43

decent announcement, all looking good here.

[doodlebug4] 22/12/2014 09:05

New contract to supply Desu Medical

RNS

RNS Number : 3876A
Collagen Solutions PLC
22 December 2014
 


22 December 2014          
 
Collagen Solutions Plc
(the "Company" or the "Group")
 
New contract with Desu Medical for the supply of soluble collagen
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its subsidiary Collagen Solutions (UK) Limited has agreed a contract with Desu Medical to supply soluble collagen. This agreement is for the manufacturing of brain dura and spinal fusion implants which will be used in the treatment of dura/spinal injuries by stimulating enhanced dura/bone generation through the use of high concentration collagen. Dura is the thick membrane that surrounds and protects the brain and spinal cord.
 
Collagen Solutions is committed to providing the highest quality collagen-based biomaterials to support medical devices and regenerative medical interventions across a wide range of applications and clinical indications. The announcement confirms that its soluble collagen will be used in the production of Desu Medical's brain and spinal implants DECOLL® and DEBONE®.
 
Dr Stewart White, CEO of Collagen Solutions plc said: "We are pleased to announce that we have reached an agreement for the supply of our soluble collagen product to Desu Medical. This agreement is the culmination of a long association with Desu Medical during which we have been supplying developmental quantities of medical grade collagen. Winning this contract is based on our ability to convince such an established Company that we can supply a medical grade collagen suitable for manufacturing their products consistently and to order, for the life of the product line. It is important for companies to secure their source of the collagen early in the commercialisation process as this will become part of the regulatory submissions for their products around the World. The long term provision of our medical grade collagen for an increasing number of products begins to unlock the value that we have in our manufacturing capabilities."
 
Dr Mehmet Sorar, CEO of Desu Medical said: "We are equally pleased to announce our agreement with Collagen Solutions. Our aim is to make our products - DEBONE® and DECOLL®, which contain up to 90% soluble collagen - leading brands in the market. We hope that our collaboration will last for many years to come."
 

[hillfoot7] 19/12/2014 16:57

Thanks,still a bit to learn just a bit of a hobby for me this stock market thingy.cheers

[the prophet] 19/12/2014 16:25

you're welcome, doodlebug4.

hillfoot, they are dealing 100 shares on line, but the MM's are all quoting in 25,000 shares, so should be able to buy, or sell, minimum of 25,000 shares.

[doodlebug4] 19/12/2014 15:28

Thank you for that info The Prophet - much appreciated.

[the prophet] 19/12/2014 13:31

There is an updated brokers note on the Collagen web-site, published yesterday



There is also a company presentation document, dated December 2014. I assume that was used in connection with the recent fund raising/RTO

[hillfoot7] 19/12/2014 12:55

Thanks,unable to buy any except through n trades

[the prophet] 18/12/2014 23:57

HillfootInstitutions declaring like Helium are the ones that took part in the placing.

[hillfoot7] 17/12/2014 17:42

Where are these institutions getting the shares from regarding the last three holding rns,very lightly traded share but sought after since the placing and recent takeover,good to see the board took a big chunk of these also,looks promising here

[the prophet] 17/12/2014 13:36

slowly ticking up, and under the radar wrt to BB's, which ain't a bad thing.

Difficult to compare COS with other companies? I don't know if Tissue Regenix (TRX) could be classed in the same category.

advfn thread on them here:


I note they have a market cap >£130m, compared to COS which is around £17m or so, but, as I say, not sure if a comparison is valid or not.

[doodlebug4] 17/12/2014 11:22

Helium Rising Stars Fund just bought in - 10.7million.

[jacobjohn7] 15/12/2014 10:06

Added. Steady burner this one...

[jacobjohn7] 15/12/2014 09:16

Excellent start, this feels verymuch off the radar....

[doodlebug4] 15/12/2014 08:36

Contract signed with Kyeron

RNS

RNS Number : 7068Z
Collagen Solutions PLC
15 December 2014
 


Collagen Solutions Plc
15 December 2014                                    (the "Company" or " Collagen Solutions")
 
Commercial supply of fibrous collagen powder agreed with KYERON
for the development of a wound management device
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its subsidiary Collagen Solutions (UK) Limited has signed an agreement with KYERON Medical Innovations (KYERON) to develop and supply fibrous collagen powder for the manufacture of a wound management device.
 
Collagen Solutions is committed to providing the highest quality, medical grade biomaterials to support medical devices and other products for regenerative medicine across a wide range of applications and clinical indications. Collagen Solutions will use its expanded development capability in the UK, US and New Zealand to develop a specific grade of fibrous collagen powder which KYERON will then formulate into a product for commercialization in the growing wound management market.
 
KYERON was formed in 2007 and is a private Dutch biomaterials company based in Enschede, the Netherlands, specialising in developing solutions to medical needs. Its products use the innovative biomaterial knowledge of the Company to produce a range of products for various orthopaedic, neurosurgical and periodontal tissue grafting procedures.
 
Dr Stewart White, Chief Executive Officer of Collagen Solutions said, "This agreement to provide our medical grade fibrous collagen is an excellent example of how we now bring together our development capability and world-recognised expertise in the manufacture of medical grade collagen products. We are capable of providing clients with a product that meets their needs precisely. We are pleased to see that KYERON has the confidence in the capabilities of Collagen Solutions to identify and manufacture consistently and in sufficient quantity, collagen products to satisfy their commercial needs as demand for their products grow.  More importantly, we can support KYERON with respect to regulatory submissions for new products containing our collagen."
 
Chief Executive Officer of KYERON, Mr. Ronny Masselink said, "We are a manufacturer of innovative products using the best available raw materials. This is a great opportunity for us to work closely with a collagen specialist that can provide us with the highest grade materials consistently. Collagen Solutions will be our partner in the development of a fibrous collagen powder to benefit those patients suffering acute and chronic wounds. We see Collagen Solutions as our preferred supplier for these raw materials for this and other collagen-based biomaterials such as bone graft substitutes. Working with them we now have access to the required state-of-art collagen technology to create our next generation of innovative products."
 

[canalet3] 15/12/2014 07:51

Good start for our new company

[doodlebug4] 12/12/2014 12:00

Reyker Nominees buying in now.

[doodlebug4] 11/12/2014 15:52

Giltspur Nominees just bought a chunk of these.

[doodlebug4] 10/12/2014 08:58

Southern Lights Biomaterials Acquisition Completed

RNS

RNS Number : 3045Z
Collagen Solutions PLC
10 December 2014
 


Collagen Solutions Plc
(the "Company" or the "Group")
 
 Southern Lights Biomaterials Acquisition Completed
 
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the completion of the acquisition of Southern Light Biomaterials ('SLB'), a profitable business converting collagen and other biological materials into value added products which are supplied to clients for further processing or by direct sales to customers.
 
The acquisition of SLB has further de-risked the Company's business model and is a logical strategic extension and complementary in nature to the Company's existing business model.
 
Benefits of the combined business:
 
·     Profit added (EBITDA of £273,911 in year ended March 2014)
·     Increased IP and know-how around biomaterial development and manufacture
·     Secure raw material from registered BSE free sources
·     Focus on creating higher value formulations of collagen
·     Critical mass as a global supplier with increased geographic reach
·     Security of production and increased capacity via additional production site
·     Wider range of processed raw materials, e.g. pericardium
·     Combined international operations in North America, Europe and New Zealand
·     New regional strength in Asia
·     Turn-key solutions using biomaterials from "source to device"
·     Geoff Bennett joins Collagen Solutions board as Chief Business Officer
 
Collagen Solutions and SLB have a complementary history, culture and strategy which makes the merger of the two businesses a logical move. The benefits of the merger include security of source material as SLB provides processed and semi processed bovine biomaterials, secured exclusively from New Zealand, a country the World Organisation for Animal Health describes as a 'negligible BSE risk' country.
 
SLB is based in the North Island of New Zealand, and benefits from being close to a readily available and consistent source of high quality and safe tissue. Like Collagen Solutions, SLB is a provider of processed and semi-processed biomaterials to medical device manufacturers and serves an increasing international client base with particular strengths in South Korea and other Asian countries where Collagen Solutions had no previous presence.
 
The acquisition gives the enlarged Group access to additional manufacturing capacity of medical grade collagen.  With the combined expertise of the two companies and access to North America and Asia it would be expected that more value added products will be demanded, increasing the price per gram that can be charged by the enlarged Group.
 
Overall the Group now:
 
·     Trades in Europe, North America and Asia
·     Benefits from a number of long term client arrangements 
·     Has a product catalogue which includes various grades of medical collagen as well as a range of other biomaterials that will be offered to the expanded Group's customer base
·     Manufactures collagen products  which are present in a range of registered products 
·     Produces medical grade collagen which should be of increased interest to medical device manufacturers
·     Has increased capacity and capability to manufacture medical grade biomaterials
·     Is working on a number of development projects which will benefit from the newly formed Collagen Solutions Group, which the Directors believe will result in higher value added sales
 
Commenting on the first day of trading of the combined Group's shares, Dr Stewart White, CEO of Collagen Solutions said: "This is a very good acquisition for Collagen Solutions.  The enlarged Group is well positioned to grow as the demand for medical grade collagen and collagen-based materials find increasing use in regenerative medicine and diagnostics. This represents a very significant step in completing the strategic aim of having a market capitalisation for the Group of £100m by 2020."
 
For additional information on Collagen Solutions, please visit www.collagensolutions.co.uk

[jacobjohn7] 04/12/2014 09:15

When is reverse takeover scheduled? And what impact on company and share price usually occurs after such an event? Cheers

[tpau] 24/11/2014 16:12

The proposed acquisition of Southern Lights Biomaterials attracted me to this company. If this deal goes through it could be a very wise strategic move

IMO DYOR

[the prophet] 24/11/2014 16:04

I note chairman David Evans has put in £500K on the placing, other directors have also taken part, excellent show of confidence.

[tpau] 24/11/2014 16:02

Nice little company this, very low market cap and shares in issue. Ticks up on little volume :)